Search Results
Your search for ,200 matches 1611 pages
Showing 51 - 100Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation
In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...
Ayurveda in Cancer Care
Guest Editor’s Note: Ayurveda, the traditional medical system that originated in India, focuses on improving overall well-being through self-care, diet, and herbal formulations. There is a growing patient interest in using Ayurveda for symptom control and to improve quality of life. In this...
Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer. Study...
Perioperative Pembrolizumab Plus Surgery and Risk-Adapted Standard Adjuvant Therapy Shows Benefit in Locally Advanced Head and Neck Cancer
Earlier this year, the first interim analysis of the phase III KEYNOTE-689 trial showed that the use of the PD-1 inhibitor pembrolizumab as part of a perioperative treatment regimen with standard-of-care surgery plus adjuvant radiotherapy (with or without cisplatin alone) improved event-free...
Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer
In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...
Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...
Medicare Advantage Audits Are Expanding
Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services (CMS) has announced plans to significantly enhance Risk Adjustment Data Validation (RADV) auditing in Medicare Advantage. Beginning immediately, CMS will audit all eligible...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma
In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...
FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...
New Data Show Nearly 50% of All Cancer Deaths Worldwide Are Attributable to Modifiable Risk Factors
New reporting in The Cancer Atlas, Fourth Edition, showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation, environmental...
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...
ACS Study Focuses on Effects of Medicaid Expansion in Low-Income Older Adults With Cancer
A recent study by researchers at the American Cancer Society (ACS) showed that Medicaid expansion was associated with an increase in Medicaid coverage, early-stage cancer diagnoses, and improved 2-year survival among individuals aged 65 or older who were diagnosed with cancer. They believe these...
Noncovalent BTK Inhibitor in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients ...
Concurrent vs Sequential Pembrolizumab With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Zandberg et al compared sequential vs concurrent pembrolizumab with chemoradiotherapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma. Study Details In the U.S. multicenter noncomparative trial, 80...
FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer
Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...
Ramucirumab Beyond Progression Plus Irinotecan in Ramucirumab-Refractory Advanced Gastric Cancer
In a Japanese phase III trial (RINDBeRG) reported in the Journal of Clinical Oncology, Sakai et al assessed whether the addition of ramucirumab to irinotecan would improve overall survival in third- or later-line treatment of patients with advanced or recurrent gastric or gastroesophageal cancer...
Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer
In a Chinese study reported in the Journal of Clinical Oncology, Yin et al attempted to develop a cell-free DNA (cfDNA) fragmentomics–based model for early detection of pancreatic ductal adenocarcinoma. Study Details The study consisted of training and validation cohorts from several Chinese...
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...
Biomarkers May Shed Light on Treatment Options for High-Risk Prostate Cancer
Researchers may have uncovered factors contributing to poor outcomes among patients with prostate cancer, according to recent findings presented by Dall’Era et al at the 2025 ASCO Annual Meeting (Abstract 5104). The findings may lead to the development of novel targeted therapies, particularly in...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
ASCO and Google Cloud Announce AI-Powered Tool That Provides Faster, Interactive Access to ASCO’s Evidence-Based Clinical Guidelines
ASCO and Google Cloud have announced a collaboration to launch an artificial intelligence (AI)-based ASCO Guidelines Assistant. Developed with Google Cloud’s Vertex AI platform and Gemini models, the tool is poised to transform how oncology professionals access and use critical clinical...
Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...
Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer
In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer. As stated by the investigators:...
FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
“Knowledge is like a lion; it cannot be gently embraced.” –South African Proverb Long-term efficacy and safety confirm that a hypomethylating agent and venetoclax is an improvement in the standard of care for patients with AML who are not eligible for intensive chemotherapy because of advanced age...
Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), accepted the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine...
FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer
The U.S. Food and Drug Administration (FDA) has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC). The FDA also...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab
In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced...
Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
FDA Expands Indication for Lu-177 Vipivotide Tetraxetan in mCRPC
On March 28, the U.S. Food and Drug Administration (FDA) expanded the indication for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen ...
Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
Advanced PD-L1–Positive NSCLC: Ivonescimab vs Pembrolizumab
In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...
FDA Approves Pembrolizumab for HER2-Positive Gastric or GEJ Cancer Expressing PD-L1
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the PD-L1 inhibitor pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
Atezolizumab Plus Carboplatin/Paclitaxel in Advanced Thymic Carcinoma
In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al found that atezolizumab plus carboplatin/paclitaxel showed promising results in patients with recurrent or metastatic thymic carcinoma. Study Details In the multicenter trial, 48 patients enrolled between June 2022 ...
Pembrolizumab and Bevacizumab in Untreated Melanoma Brain Metastases
In a phase II trial reported in Journal of Clinical Oncology, Weiss et al found that the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melanoma brain metastases. Study Details In the trial, 37 patients, enrolled at Yale Cancer Center and Moffitt...
Addition of Pembrolizumab to Chemotherapy for Previously Treated Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previously treated metastatic castration-resistant prostate cancer. Study Details In the global...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
Novel CD19-1XX CAR With Calibrated Signaling in LBCL
In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology
Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
New Blood-Based Screening Test Accurately Detects Colorectal Cancer Risk in Adults Aged 45 and Older
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.1 Although screening for colorectal cancer through colonoscopy or sigmoidoscopy is effective in detecting the...
Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
